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OBJECTIVES We sought to assess the hemodynamics of exercise in patients with hypertrophic cardiomy-
opathy (HCM), with and without an exercise-induced abnormal blood pressure (BP)
response, by ambulatory radionuclide monitoring of left ventricular (LV) function with the
VEST device (Capintec Inc., Ramsey, New Jersey).
BACKGROUND Blood pressure fails to increase 20 mm Hg during exercise in about one-third of patients
with HCM. This carries a high risk of sudden death.
METHODS Forty-three patients with HCM and 14 control subjects underwent maximal symptom-
limited exercise on a treadmill during VEST. The VEST data were averaged for 1 min and
analyzed at baseline, 3 min and peak exercise. The LV end-diastolic, end-systolic and stroke
volumes, cardiac output and systemic vascular resistance were expressed as the percentage of
baseline.
RESULTS Ejection fraction and stroke volume fell in patients with HCM, although they increased in
control subjects (p  0.001 and p  0.002, respectively). Cardiac output increased
significantly more in control subjects than in patients with HCM (p  0.001). In 17 patients
with HCM (39%) with an abnormal BP response, ejection fraction and stroke volume fell
more (p  0.032 and p  0.009, respectively) and cardiac output increased less (p  0.001)
than they did in patients with HCM with a normal BP response. Systemic vascular resistance
decreased similarly in patients with HCM, irrespective of the BP response.
CONCLUSIONS In patients with HCM with and without an abnormal BP response, abnormal hemodynamic
adaptation to exercise was qualitatively similar but quantitatively different. An abnormal BP
response was associated with exercise-induced LV systolic dysfunction. This causes hemo-
dynamic instability, associated with a high risk of sudden cardiac death. (J Am Coll Cardiol
2002;40:278–84) © 2002 by the American College of Cardiology Foundation
Sudden cardiac death is an ominous complication of hyper-
trophic cardiomyopathy (HCM), especially in adolescents
and young adults, and it may be the first clinical manifes-
tation in previously asymptomatic patients (1,2). An abnor-
mal blood pressure (BP) response during exercise occurs in
about one-third of patients with HCM, and it has been
associated with a high risk of sudden cardiac death, as it may
lead to hemodynamic instability, which may trigger life-
threatening arrhythmias (1,3–6).
The mechanism responsible for exercise-induced abnor-
mal BP in patients with HCM is still debated. Counihan et
al. (3) and Frenneaux et al. (4) reported that an abnormal
BP response to exercise was associated with an excessive fall
in systemic vascular resistance during exercise, due to a
peripheral vasodilatory mechanism. Conversely, a more
recent study demonstrated that an abnormal BP response
during exercise was associated with the development of
subendocardial ischemia in patients with HCM (7), thus
implying a central mechanism, through a decline in left
ventricular (LV) systolic function.
In patients with HCM, myocardial ischemia without
significant coronary artery stenosis has been demonstrated
by fixed or reversible defects (8) or cavity dilation during
exercise thallium perfusion (7), myocardial lactate produc-
tion during atrial pacing (9) and positron emission tomog-
raphy (10). Moreover, ischemia-related LV systolic dys-
function during exercise has been observed in about one-
half of patients with HCM during exercise (11,12).
The aim of our study was to assess the effects of exercise
on hemodynamics in patients with HCM with and without
an abnormal BP response to exercise, as well as in healthy
subjects, by ambulatory radionuclide monitoring of LV
function (VEST), a method that reliably allows the assess-
ment of LV function.
METHODS
Patient group. Fifty-three consecutive patients with HCM
were enrolled from our cardiomyopathy outpatient clinic at
Federico II University School of Medicine. The diagnosis of
HCM was based on echocardiographic evidence of hyper-
trophied, nondilated LVs, without an apparent cause, such
as systemic hypertension and aortic stenosis (13,14). All
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patients were in normal sinus rhythm. All cardioactive
medications were withdrawn for at least five half-lives
before the study in patients with HCM. Ten patients were
subsequently excluded upon acknowledging the inadequa-
cies of VEST: movement of the detector in three patients,
gating problems in three patients and technical problems
with the recorded data in four patients. The remaining 43
patients with HCM (age 37  14 years [range 16 to 64
years]; 33 men and 10 women) were included in the final
study group.
Fifteen age- and gender-matched healthy subjects with
no history of cardiovascular disease, a normal clinical exam-
ination (including BP) and a normal surface electrocardio-
gram (ECG), volunteered to enroll in the study and served
as the control group. One control subject was subsequently
excluded because of VEST detector movement. The re-
maining 14 control subjects (age 36  13 years [range 23 to
60 years]; 9 men and 5 women) were included in the final
study group.
Echocardiography. Each subject underwent M-mode and
two-dimensional echocardiography, followed by color flow
imaging and pulsed and continuous wave Doppler ultra-
sonography. Echocardiography was performed using a
Hewlett-Packard ultrasonic scanner (Sonos 1000, Andover,
Massachusetts) equipped with 2.5-MHz and 1.9-MHz
transducers. M-mode echocardiograms were obtained from
the two-dimensional images under direct anatomic visual-
ization. Left atrial, LV end-diastolic and LV end-systolic
diameters were measured according to the guidelines of the
American Society of Echocardiography (15) and were nor-
malized for body surface area. Left ventricular hypertrophy
was evaluated from the short-axis view by dividing the LV
wall into four segments at the level of mitral valve and
papillary muscle (16). An index of the extent of LV
hypertrophy was calculated by adding the maximal wall
thickness measured (at either the mitral valve or papillary
muscle level) in each of the four ventricular segments
(anterior and posterior septum and posterior and lateral
walls) (17,18).
Color flow Doppler imaging was used for identifying and
semiquantitatively estimating mitral regurgitation (19). The
LV outflow tract gradient was recorded both at rest and
during provocation by amyl nitrite inhalation, with a 1.9-
MHz nonimaging transducer, using the simplified Bernoulli
equation: P  4V2, where P  pressure and V  flow
velocity. Care was taken to distinguish the ejection velocity
from the mitral regurgitation jet (20).
Radionuclide angiography. Red blood cells were labeled
in vivo with 15 to 20 mCi of technetium-99m. Each subject
underwent equilibrium radionuclide angiography in the
supine position, under control conditions, to determine the
basal LV ejection fraction. Counts were collected by a small
field-of-view Anger camera (LEM ZLC, Siemens Gamma-
sonics, Des Plaines, Illinois), in a 45° left anterior oblique
projection with a 15° craniocaudal tilt. Images were acquired
with 2 digital zoom in frame mode by ECG gating at a
framing rate of 30 frames/cardiac cycle on a dedicated
computer system. Radionuclide angiograms were analyzed
with standard commercial software (Starcam 300 A/M,
General Electric, Milwaukee, Wisconsin). The ejection
fraction was computed on the raw time-activity curve.
Accuracy and reproducibility of measurements in our labo-
ratory have been reported previously (21).
VEST. Immediately after radionuclide angiography, the
VEST detector (Capintec, Inc., Ramsey, New Jersey) was
placed over the subject’s chest and tightened to ensure stable
contact. Because VEST is a nonimaging device, it was
positioned under gamma camera control over the LV (22).
At the end of the protocol, a 30-s static image was obtained
to confirm that the radionuclide detector had not moved
during recording. At the end of monitoring, data were
reviewed for technical adequacy. Briefly, the average count
rate (decay-corrected) of the entire recording was displayed:
if the curve had abrupt10% deviation from a straight line,
the VEST study was considered inadequate: sudden shifts
in the slope of the line indicate detector movement or
instrument malfunction (22,23). Radionuclide and ECG
data were averaged for 60-s intervals and analyzed at
baseline, 3 min and peak exercise. The ejection fraction was
computed as stroke counts divided by the background-
corrected end-diastolic counts. Background was determined
by matching the initial rest VEST ejection fraction value to
that obtained by the gamma camera. Systemic vascular
resistance was calculated according to the following for-
mula: 80  (mean arterial pressure / LV cardiac output).
The LV end-diastolic, end-systolic and stroke volumes,
cardiac output and systemic vascular resistance were consid-
ered to be 100% at the beginning of the study and were
subsequently expressed relative to this value.
Exercise test. All patients and control subjects underwent
maximal symptom-limited treadmill exercise testing using
the Bruce protocol (24). The test duration was measured in
seconds. Blood pressure was measured using a cuff sphyg-
momanometer at rest, 1-min intervals during exercise and
1-min intervals for 5 min during the recovery period after
exercise. A normal BP response was defined as a gradual
increase of a least 20 mm Hg in systolic BP during exercise.
An abnormal BP response was considered, according to
most studies, as: 1) an increase or decrease in systolic BP
20 mm Hg during exercise, compared with baseline; 2) an
initial increase in systolic BP with a subsequent fall of
20 mm Hg, compared with peak BP; and 3) a continuous
decrease in systolic BP20 mm Hg throughout the exercise
Abbreviations and Acronyms
ANOVA  analysis of variance
BP  blood pressure
ECG  electrocardiogram
HCM  hypertrophic cardiomyopathy
LV  left ventricular
VEST  ambulatory radionuclide monitoring device
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test, compared with baseline (3–6). These last two condi-
tions are termed “hypotensive BP response,” whereas the
first one represents a flat response. A three-lead ECG
monitor allowed continuous evaluation of the heart rate,
rhythm, T-wave and ST-segment.
Statistical analysis. Data are expressed as the mean value
 SD in the text and tables; however, in order for the
figures to be more easily readable, standard errors of the
mean value are provided there. The chi-square test with
Yate’s correction for continuity was used to analyze cate-
gorical variables. Normal distribution of all continuous
variables, including the percent differences from peak to
baseline, was tested using the one-sample Kolmogorov-
Smirnov test. All variables were normally distributed; para-
metric tests were therefore used. The unpaired Student t test
was performed to determine differences between mean
values for continuous variables, as appropriate. The differ-
ence in the time courses of parameters between groups was
analyzed by two-way analysis of variance (ANOVA) for
repeated measures. Interactions between the time course of
parameters and groups were tested as: time course groups.
If any interactions were significant, a post-hoc comparison
was performed using the unpaired t test with Bonferroni
correction to detect differences between two groups at given
time points. For descriptive purposes, the effect of exercise
within each group was analyzed by one-way ANOVA for
repeated measures.
A p value 0.05 was considered statistically significant.
All statistical calculations were performed by SPSS for
Windows, release 10.0 (SPSS Inc., Chicago, Illinois).
RESULTS
Patient characteristics. The clinical, echocardiographic
and radionuclide baseline characteristics of the 43 patients
with HCM and the 14 control subjects are shown in Table
1. Patients with HCM had a smaller LV end-systolic
dimension, a larger maximal left atrial dimension and a
higher baseline ejection fraction, compared with control
subjects.
Hemodynamics during exercise. The achieved level of
exercise was maximal in 10 control subjects (73%) and 19
patients with HCM (44%): the test was interrupted because
of fatigue in 4 control subjects (27%) and 12 patients (28%)
and because of shortness of breath and/or angina in 12
patients (28%). In one patient, the exercise test was stopped
because syncope occurred. The mean exercise duration was
similar between the two groups.
During exercise, the heart rate increased significantly
(p  0.001 by one-way ANOVA) and similarly in patients
with HCM and control subjects (percent difference between
peak exercise and baseline: 84  22% and 90  35%,
respectively; p  NS by two-way ANOVA).
Systolic BP during exercise increased significantly more
in control subjects than in patients with HCM (36  16%
vs. 22  23%, respectively, over baseline; p  0.032 by
two-way ANOVA).
The LV end-diastolic volume did not change signifi-
cantly throughout exercise in control subjects (9  7% over
baseline; p  NS by one-way ANOVA), but it rose in
patients with HCM (15  7% over baseline; p  0.001 by
one-way ANOVA). There were significant differences in
end-systolic volume changes during exercise between con-
trol subjects and patients with HCM; in fact, the end-
systolic volume increased less in control subjects than in
patients with HCM (2  20% and 41  25%, respectively,
over baseline; p  0.001 by two-way ANOVA). Ejection
fraction (Fig. 1) and stroke volume (Fig. 2) changes were
significantly different between control subjects and patients
with HCM. They rose in control subjects (10  19% and
21  27% for ejection fraction and stroke volume, respec-
tively, over baseline), whereas they fell in patients with
HCM (20  21% and 5  27%, respectively, over
baseline). Cardiac output increased significantly more in
control subjects than in patients with HCM (132 70% vs.
Table 1. Clinical, Echocardiographic and Radionuclide Baseline









Age (yrs) 37  14 36  13 NS
Male gender (%) 32 (74%) 9 (64%) NS
Left atrial diameter (mm) 44  6 32  3 0.001
LV end-diastolic
diameter (mm)
45  6 48 2 NS
LV end-systolic
diameter (mm)
25  5 32  3 0.001
Maximal LV wall
thickness (%)
21  5 9  1 0.001
Ejection fraction (%) 71  11 60  5 0.001
Peak filling rate
(stroke counts/s)
3.2  1.0 3.0  0.8 NS
Exercise duration (s) 498  136 558  114 NS
Data are presented as the mean value  SD or number (%) of patients or control
subjects.
HCM  hypertrophic cardiomyopathy; LV  left ventricular; NS  not
significant.
Figure 1. Mean value  SEM of ejection fraction (%) measured at
baseline, 3 min and peak exercise in the two study groups (squares 
control subjects; diamonds  patients with hypertrophic cardiomyopathy
[HCM]). The p value reflects two-way analysis of variance for repeated
measures. *p  0.001 vs. patients with HCM, as tested by post-hoc
analysis.
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78  50%, respectively, over baseline; p  0.001 by
two-way ANOVA).
Systemic vascular resistance fell during exercise in control
subjects and patients with HCM (both p  0.001 by
one-way ANOVA), but more so in control subjects (43
14% vs.30 20%); however, this difference did not reach
statistical significance (Fig. 3).
Hemodynamic adaptation in patients with HCM with
exercise-induced abnormal systolic BP. Seventeen pa-
tients with HCM (39%) showed an abnormal BP response
to exercise: in 3 patients with HCM, systolic BP fell by
more than 20 mm Hg from the start of exercise (rest value);
in 10 patients, there was an appropriate initial increase in
systolic BP, with a subsequent fall of at least 20 mm Hg
from peak BP. The remaining four patients had a flat BP
response to exercise.
The baseline characteristics of patients with HCM with a
normal versus abnormal BP response to exercise are shown
in Table 2. The patients with HCM with exercise-induced
abnormal BP were significantly younger than those with a
normal BP response (age 42  14 years [range 18 to 64
years] and 31 12 years [range 16 to 51 years], respectively;
p  0.011).
The mean exercise duration was similar between the two
HCM groups. During exercise, the heart rate rose signifi-
cantly and similarly (both p  0.001 by one-way ANOVA)
in patients with HCM with a normal systolic BP response
and exercise-induced abnormal BP (94  40% and 85 
24%, respectively, over baseline). The ejection fraction
increased slightly in patients with HCM with a normal
systolic BP response at 3 min over baseline and significantly
fell at peak exercise (Fig. 4). Patients with an abnormal BP
response had a similar pattern of changes; the magnitude of
the peak ejection fraction decrease was greater in patients
with an abnormal BP response than in those with a normal
response (31  16% and 13  20%, respectively, over
baseline). Likewise, changes in stroke volume during exer-
cise were significantly different (Fig. 5) between patients
with HCM with a normal versus abnormal systolic BP
response to exercise. In fact, stroke volume increased in
patients with HCM with a normal BP response to exercise,
whereas it fell in patients with HCM with an abnormal BP
response (2  27% and 18  21%, respectively, over
baseline). As a consequence, the increase in cardiac output
was significantly different (p 0.001 by two-way ANOVA)
between patients with HCM with a normal BP response
and those with an abnormal response to exercise (96  47%
and 51  41%, respectively, over baseline). Systemic vascu-
lar resistance decreased similarly (both p  0.001 by
one-way ANOVA) (Fig. 6) in patients with HCM without
and with an abnormal BP to exercise (33  20% and
32  26%, respectively, over baseline).
DISCUSSION
Hemodynamic adaptation to exercise. In this study, we
demonstrated that patients with HCM show an abnormal
hemodynamic adaptation to exercise, as compared with
control subjects. Patients with HCM and control subjects
showed a similar duration of exercise and maximal achieved
heart rate, but there was a significant difference in LV
systolic function. In fact, the ejection fraction (Fig. 1) and
stroke volume (Fig. 2) increased significantly in control
subjects, whereas they fell in patients with HCM. Further-
more, cardiac output increased significantly less in patients
with HCM than in control subjects. An impaired systolic
response to exercise in patients with HCM was due to the
combination of a significant increase in LV end-diastolic
and, more so, in end-systolic volumes. This suggests that a
potential mechanism for such an abnormal response to
exercise in patients with HCM may be myocardial ischemia.
Myocardial ischemia has been clearly demonstrated in
patients with HCM (7–12,25) and is a major risk factor for
sudden cardiac death (26). It could be induced by an
increased myocardial oxygen demand (27), such as occurs
during exercise. Our findings were consistent with previous
studies that demonstrated exercise-induced myocardial isch-
emia during VEST monitoring in patients with coronary
artery disease (28) in whom exercise-related myocardial
ischemia caused a fall in the ejection fraction and an increase
in end-systolic and end-diastolic volumes. Similarly, Taki et
Figure 3. Mean value  1 SEM of systemic vascular resistance (%)
measured at baseline, 3 min and peak exercise in the two study groups
(squares  control subjects; diamonds  patients with hypertrophic
cardiomyopathy). The p value reflects two-way analysis of variance for
repeated measures.
Figure 2. Mean value 1 SEM of percent difference in stroke volume (%)
between peak exercise and baseline in the two study groups: control
subjects and patients with hypertrophic cardiomyopathy (HCM).
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al. (11) demonstrated that LV dysfunction during exercise,
as assessed by VEST, is a common phenomenon in patients
with HCM, and they postulated that it was due to myocar-
dial ischemia. In a recent report, Okeie et al. (12) showed
that myocardial ischemia was the primary reason for the
decrease in ejection fraction in patients with HCM during
exercise, as assessed by VEST. This was associated with the
development of dobutamine-induced new wall motion ab-
normalities. Besides, there was a significant correlation
between changes in ejection fraction and the number of
dysfunctional LV segments (12).
Hemodynamics of exercise-induced abnormal BP. An
abnormal BP response to exercise has been regarded as
evidence for hemodynamic instability and has been pro-
posed as a marker of an increased risk of sudden cardiac
death in patients with HCM (1,3,4), especially in young
patients (5,6). In our study, 13 patients with HCM (30%)
showed a hypotensive systolic BP response to exercise and 4
(9%) showed a flat response.
Patients with HCM with an abnormal BP response to
exercise were younger than those with a normal systolic BP
response, according to previous studies (5,6). Furthermore,
they exhibited a more abnormal hemodynamic adaptation to
exercise and impairment in systolic function, as shown by a
more pronounced fall in ejection fraction (Fig. 4), stroke
volume (Fig. 5) and cardiac output. Hence, the mechanism
for exercise-induced abnormal BP could be a cascade from
marked LV systolic dysfunction, to a decrease in cardiac
output and finally to hypotension. Thus, we hypothesize a
“central” mechanism responsible for abnormal BP during
Table 2. Clinical, Echocardiographic and Radionuclide Baseline Characteristics of Patients With
HCM With a Normal Blood Pressure Response (HCM Normal Response) and Patients







(n  17) p Value
Age (yrs) 42  14 31  12 0.011
Male gender (%) 22 (85%) 11 (65%) NS
Family history of sudden cardiac death (%) 3 (12%) 7 (41%) NS
NYHA functional class 2 (%) 7 (28%) 8 (47%) NS
History of angina (%) 3 (12%) 6 (35%) NS
History of syncope (%) 7 (28%) 3 (18%) NS
Left atrial diameter (mm) 44  7 44  5 NS
Left atrial fractional shortening (%) 20  8 21  7 NS
LV end-diastolic diameter (mm) 46  6 44  4 NS
Incidence of LV outflow tract obstruction
30 mm Hg at rest or 50 mm Hg
during stimulation by amyl nitrate
inhalation (%)
11 (44%) 8 (47%) NS
Maximal LV wall thickness (mm) 22  5 21  4 NS
Degree of LV hypertrophy (mm) 66  14 61  11 NS
Ejection fraction (%) 72  12 72  5 NS
Peak filling rate (stroke counts/s) 3.1  1.0 3.2  1.2 NS
Exercise duration (s) 514  130 474  147 NS
Data are presented as the mean value  SD or number (%) of patients or control subjects.
NYHA  New York Heart Association; other abbreviations as in Table 1.
Figure 4. Mean value  SEM of ejection fraction (%) measured at
baseline, 3 min and peak exercise in the two study groups (squares 
patients with hypertrophic cardiomyopathy [HCM] and a normal systolic
blood pressure [BP] response to exercise; diamonds patients with HCM
and an abnormal systolic BP response to exercise). The p value reflects
two-way analysis of variance for repeated measures. *p  0.003 vs. HCM
abnormal response, as tested by post-hoc analysis.
Figure 5. Mean value  SEM of percent difference in stroke volume (%)
between peak exercise and baseline in the two study groups: patients with
hypertrophic cardiomyopathy (HCM) and a normal systolic blood pressure
(BP) response to exercise and patients with HCM and an abnormal systolic
BP response to exercise.
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exercise. In patients with coronary artery disease, exercise-
induced hypotension is strictly associated with severe coro-
nary artery disease and is related to global and regional LV
systolic dysfunction (29,30).
Our results complement those of Yoshida et al. (7), who
demonstrated that in patients with HCM, an exercise-
induced hypotensive response was related to subendocardial
ischemia, as assessed by thallium scintigraphy, with a higher
prevalence of LV cavity dilation than in those with a normal
BP response. Our findings shed light on the mechanism by
which subendocardial ischemia is related to an abnormal BP
response.
An exercise-induced BP fall was abolished by alcohol
ablation of the septum in patients with HCM with LV
outflow tract obstruction (31). Because LV outflow tract
obstruction is a major determinant of oxygen consumption
in patients with HCM, its decrease should reduce or abolish
exercise-induced ischemia. This suggests a central mecha-
nism, rather than a peripheral mechanism, for an abnormal
BP response to exercise in patients with HCM.
Previous studies (3,4) have suggested that in patients with
HCM, exercise-induced hypotension was due to an exag-
gerated decrease in systemic vascular resistance. These
investigators assessed systemic vascular resistance from the
forearm blood flow, and they supposed that activation of
ventricular mechanoreceptors may relate to exercise-induced
hypotension or increased sensitivity of arterial baroreflex,
hence a “peripheral” mechanism. In our study, we assessed
global systemic vascular resistance indirectly, as the ratio of
mean BP to cardiac output, and we showed a similar
decrease in systemic vascular resistance during exercise in
patients with HCM with exercise-induced hypotension and
in patients with a normal BP response to exercise. The
difference in systemic vascular resistance responses during
exercise between these previous studies and ours may be
explained by the difference in methods; in fact, systemic
vascular resistance changes differently in different regions.
Global systemic vascular resistance is the sum of different
adaptation processes to exercise: the local effect of exercise
metabolites, cortical influences, reflex activation of meta-
bolic receptors in skeletal muscle and increased ventricular
baroreceptor activity (32). Therefore, it is reasonable that
local changes in resistance do not reflect modifications in
global systemic vascular resistance.
An alternative explanation is that an abnormal decrease in
systemic vascular resistance may cause or aggravate ongoing
myocardial ischemia during exercise. Nevertheless, this
hypothesis is unlikely, because in our study systemic vascular
resistance showed a similar decrease during exercise in
patients with HCM with and without exercise induced-
hypotension.
Study limitations. The VEST monitoring is a functional
tool that assesses relative LV volume curves. We hypothe-
size that the mechanism responsible for exercise-induced
abnormal BP be myocardial ischemia; nevertheless, we only
have evidence of exercise-induced systolic dysfunction, with
a fall in stroke volume, ejection fraction and, hence, cardiac
output.
Conclusions. Patients with HCM showed an abnormal
hemodynamic adaptation to exercise, with LV systolic
dysfunction likely due to exercise-related myocardial is-
chemia, as compared with control subjects.
One-third of patients with HCM had an abnormal
systolic BP response to exercise. The abnormal hemody-
namic adaptation to exercise in patients with HCM with
and without an abnormal BP response to exercise was
qualitatively similar but quantitatively different and may
have a common denominator in exercise-related myocardial
ischemia. Exercise-induced abnormal BP was associated
with exercise-induced LV systolic dysfunction, and this
causes hemodynamic instability, which may be responsible
for the high risk of sudden cardiac death.
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